Cannabis Law and Access in Italy

Italy's cannabis framework: not as simple as "legal" or "illegal"

Forty-three. That's roughly the number of countries I've mapped scheduling frameworks for over the past two years, and Italy keeps landing in my notes as one of the harder ones to summarise cleanly. Not because the laws are hidden , they're publicly available , but because the gap between what the statute says and what happens on the ground is genuinely wide. If you've seen headlines calling Italy "cannabis-friendly," hold that thought.

A quick note before we go further: this article describes Italian law for educational purposes. It has no bearing on what is legal in Australia. AU residents are subject to the Therapeutic Goods Act 1989, the Poisons Standard (the SUSMP), and their relevant state or territory legislation. If you're after how the Australian access system works, our glossary pages on the Special Access Scheme, Authorised Prescriber pathway, and Schedule 8 (Controlled Drug) classification are a better starting point.

The legislative backbone: DPR 309/1990 and what came after

Italy's foundational drug law is the Testo Unico sulle droghe , the Consolidated Law on Drugs; enacted by Presidential Decree No. 309 of 1990 (DPR 309/1990). Cannabis sits on Table I of that decree, alongside other controlled substances. Possession and use for personal purposes is technically a civil rather than criminal matter under article 75, following a 2014 Constitutional Court ruling that struck down harsher mandatory minimums. But supply and trafficking remain criminal offences with significant penalties.

That 2014 ruling (Corte Costituzionale, judgment 32/2014) is worth flagging specifically: it rebalanced the penalty structure that had been introduced by the Fini-Giovanardi Law of 2006, which had controversially equalised penalties for "soft" and "hard" drugs. After the ruling, personal possession of small quantities sits in an administrative grey zone, possible sanctions include licence suspensions, not imprisonment, but the threshold for "personal use" versus "intent to supply" is determined case by case, by a prefect, and is not codified as a fixed gram limit in the way some other jurisdictions handle it. That ambiguity is real and consequential.

Medical cannabis: the Farmacie Militari model

Italy legalised medical cannabis in 2007 under Law 49/2006 amendments and subsequent ministerial decrees. The practical structure is unusual by international standards: the Stabilimento Chimico Farmaceutico Militare (SCFM) in Florence; a military pharmaceutical facility, holds the mandate to produce cannabis for medical use domestically. It's been operating under that mandate since 2016. Import is also permitted; the Netherlands' Office of Medicinal Cannabis has historically been a significant supplier to the Italian market, given domestic production has struggled to meet demand.

Prescriptions are issued by physicians and dispensed through the national health service (SSN) pharmacy network, though reimbursement by the SSN varies substantially by region, a point that generates real frustration among Italian patient advocates. Some regions fully reimburse, others don't. The active compounds in these preparations include THC and CBD in various ratios, and the products are standardised preparations rather than consumer retail items.

I'll be honest: the regional reimbursement patchwork strikes me as a structural flaw. A system where your access to an approved medicine depends on which side of an administrative border you live on is inequitable by design, and Italy's own parliamentary debates have reflected that tension without fully resolving it.

Cannabis light: the 2016 law and the Supreme Court's 2019 ruling

Law 242 of 2016 is where things get genuinely complicated. It was framed as an agricultural law promoting hemp cultivation (Cannabis sativa L.) for industrial purposes; fibre, seeds, food, cosmetics. It set a THC threshold of 0.2% for cultivation, with a tolerance ceiling of 0.6%. What it did not explicitly authorise was the retail sale of dried hemp flowers for human consumption.

That ambiguity spawned an entire industry. Between 2016 and 2019, hundreds of "cannabis light" shops opened across Italy, Rome, Milan, Bologna, Naples, selling low-THC dried flower. The commercial framing was careful: marketed as collectibles, for aromatherapy, not for smoking. Whether anyone believed that framing is a separate question.

In May 2019, Italy's Court of Cassation (Sezioni Unite) issued a ruling that these products were not covered by Law 242 and that their sale could, in principle, constitute a criminal offence. That sent a shockwave through the sector. In practice, enforcement remained inconsistent; prosecutions were rare, shops largely stayed open, but the legal cloud has never fully lifted. The European Court of Justice added a wrinkle in November 2020 (Case C-663/18), holding that EU free movement principles prevent member states from prohibiting the sale of CBD products lawfully produced in another EU state, which created a partial counterweight to the 2019 Italian ruling. The intersection of those two decisions is, as of writing, still not cleanly resolved in Italian case law.

The cannabidiol in those hemp-derived products binds differently to cannabinoid receptors than THC does, if you want the receptor-level picture, the endocannabinoid system and CB1 receptor glossary pages explain the mechanism. The legal debate, though, has nothing to do with pharmacology and everything to do with taxonomy; specifically, whether a dried hemp flower is an "industrial hemp product" or a "narcotic substance."

Recreational use: still illegal, still widespread

There is no legal recreational market in Italy. Full stop. Personal possession sits in that administrative grey zone described above, but cultivation beyond licensed hemp farming is a criminal matter. Referenda on decriminalisation have been attempted, most recently in 2022, when a referendum effort collected over 630,000 signatures before the Constitutional Court ruled the question inadmissible on technical grounds in February 2022. That ruling disappointed reform advocates and effectively shelved the debate for that electoral cycle.

Italy's cannabis consumption statistics, per the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), consistently place it among the higher-use EU member states. That gap between prevalence and legal status is a recurring theme in European drug policy, and Italy is far from alone in sitting with it unresolved.

THC limits, labelling, and what this means for the "cannabis light" product category

Under the current framework, hemp products sold commercially must not exceed 0.2% THC (with the 0.6% cultivation tolerance). CBD content is not itself regulated as a drug threshold in the same way, but novel food regulations at the EU level (the European Food Safety Authority's 2019 classification of CBD extracts as novel foods) added another layer of compliance complexity for any product intended for ingestion.

The terpene profiles of these products; myrcene, beta-caryophyllene, linalool and others, fall outside the scheduled substance framework entirely. They're not controlled. But when they appear in a dried flower alongside even trace THC, the whole product's legal status depends on which court is looking at it and which reading of Law 242 they favour. That's not a comfortable place for any commercial operator.

What Australian readers should take from this

The short version: Italy has a functioning medical cannabis programme with real physician prescribing, a murky industrial hemp retail sector with unresolved case law, and no legal recreational market. It is not the free-access jurisdiction that some popular summaries suggest.

For Australians curious about how domestic access works by comparison, our Schedule 4 (Prescription Only) and Schedule 8 frameworks, the TGA's ARTG listing requirements, and Good Manufacturing Practice standards; those are separate systems with their own logic. I've spent enough weekends cross-referencing the Poisons Standard with my survey maps (and neglecting Trevor the sourdough starter) to say with confidence: no two countries land in quite the same place on this, and summaries that flatten the differences are doing readers a disservice.

Sources

• Italy Drug Report 2023, European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• DPR 309/1990, Testo Unico sulle droghe; Normattiva (Italian Official Law Portal)
• Case C-663/18, Court of Justice of the European Union (CJEU)
• Medicinal Cannabis Guidance Documents, Therapeutic Goods Administration (TGA)

, Marcus Hale, Regulatory researcher; TGA & access law